What happens when the institutions we trust to determine what is true also have the power to silence people who challenge them? Independent journalist, researcher and author Jeremy R. Hammond joins me for a provocative conversation about censorship, public-health messaging, informed consent—and how difficult it has become to distinguish legitimate disagreement from “misinformation.” We dig into examples from COVID-era censorship, natural immunity, vaccine research, observational studies, healthy-user bias, lockdowns, the lab-origin debate and the relationship between government agencies, media and industry. But the larger question is bigger than COVID: How do we learn to think for ourselves when information is overwhelming, institutions disagree, algorithms reward outrage, and every one of us has confirmation bias? Jeremy makes the case for going back to primary sources, examining how studies are actually designed, looking for conflicting evidence and learning to reconcile it rather than simply choosing the narrative we already prefer. We also talk about the importance of resisting rage bait, questioning our own echo chambers and becoming active—not passive—consumers of information. In this episode How “misinformation” gets definedJeremy’s experience being censored on LinkedInNatural immunity and COVID-era public-health messagingThe difference between randomized trials and observational studiesHealthy-user bias and why correlation can misleadLockdowns, masks and comparing outcomes across populationsThe Proximal Origin paper and the COVID lab-origin debateGovernment, industry and conflicts of interestConfirmation bias—even when we think we’re the ones questioning authorityHow to investigate claims using primary sourcesUsing AI without simply outsourcing your thinkingBuilding communities where disagreement and critical thinking are allowedConnect with Jeremy Jeremy R. HammondJeremyRHammond.com Jeremy’s Truth Action Network and free newsletter are available through his website. Primary Sources León TM, et al. “COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021.” CDC Morbidity and Mortality Weekly Report (MMWR). 2022;71:125–131.CDC. “New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection.” August 6, 2021.Jamison AM, et al. “Vaccine-related advertising in the Facebook Ad Archive.” Vaccine. 2020;38(3):512–520.Ferguson NM, et al. “Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.” Imperial College COVID-19 Response Team, Report 9. March 16, 2020.Seow J, et al. “Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.” Nature Microbiology. 2020;5:1598–1607.Benn CS, Schaltz-Buchholzer F, Nielsen S, Netea MG, Aaby P. “Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects?” iScience. 2023;26(5):106733.Thomas SJ, et al. “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.” New England Journal of Medicine. 2021;385:1761–1773.El Sahly HM, et al. “Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.” New England Journal of Medicine. 2021;385:1774–1785.Simonsen L, et al. “Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population.” Archives of Internal Medicine. 2005;165(3):265–272.Jackson LA, et al. “Evidence of bias in estimates of influenza vaccine effectiveness in seniors.” International Journal of Epidemiology. 2006;35(2):337–344.Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. “The proximal origin of SARS-CoV-2.” Nature Medicine. 2020;26:450–452.Calisher C, et al. “Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19.” The Lancet. 2020;395(10226)–e43